Vimian is a Swedish animal-health group built around specialty businesses in veterinary pharmaceuticals, diagnostics, medtech and related services. Its portfolio targets companion-animal and other veterinary customers with niche products and technologies rather than broad farm-animal commodity lines. The model emphasizes growth through focused animal-health platforms serving clinics, specialists and animal owners.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q4 2024 | 104.9 | — | 12.2 | 33.4% |
| Q1 2025 | 107.5 | — | 4.3 | -53.9% |
| Q2 2025 | 104.3 | — | 8.3 | -19.7% |
| Q4 2025 | 109 | 3.9% | 12.1 | -0.8% |
| Q1 2026 | 116 | 7.9% | 9.8 | 127.9% |
| Q2 2026 | 121.6 | 16.6% | 8.4 | 1.2% |
All markets — KeepWinning global stock screener
Other companies on Stockholm: PPI Public Property Invest AB (publ) (PUBLI), Alvotech (ALVO SDB), NCC AB (publ) (NCC A), NCC AB (publ) (NCC B), Kinnevik AB (KINV B), Attendo AB (publ) (ATT)